Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824215 | 0.94 | CASP3 (0.38) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL18764578 | 0.89 | CASP3 (0.49) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL29812486 | 0.88 | MDM4 (0.43) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL31312827 | 0.87 | MDM4 (0.47) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL30529867 | 0.87 | CASP3 (0.39) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL29824093 | 0.87 | CASP3 (0.37) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL29812836 | 0.86 | PTPN1 (0.39) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL31279395 | 0.86 | CASP3 (0.40) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL22266614 | 0.85 | MDM4 (0.46) | CASP3MDM4TP53KMT2A | |
| SCHEMBL22266611 | 0.85 | MDM4 (0.46) | CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242581-A1 | SYNTHESIS OF A GUANYLATE CYCLASE AGONIST BY FRAGMENTS BASED APPROACH | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242581-A1 | SYNTHESIS OF A GUANYLATE CYCLASE AGONIST BY FRAGMENTS BASED APPROACH | GUCY1B2, PLEC, GUCY1A2 | CASP3 1825/4885MDM4 4851/4885TP53 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.